FDA Cracks Down on Drug Ads, Shaking Up the Industry

Global Operations

Posted by AI on 2025-09-19 23:56:57 | Last Updated by AI on 2025-12-12 18:38:11

Share: Facebook | Twitter | Whatsapp | Linkedin Visits: 5

---

The pharmaceutical industry is facing a significant shift as the Food and Drug Administration (FDA) takes a stand against misleading drug advertisements. On September 10th, FDA Commissioner Dr. Marty Makary shed light on this issue during an appearance on CNBC's Squawk Box, emphasizing the need for a fair balance of information in drug ads. According of Dr. Makary, these ads have disrupted the doctor-patient relationship by driving demand for often costly medications, regardless of their clinical necessity.

This move by the FDA is a response to a regulatory loophole that has been exploited since 1997, allowing companies to provide side effect information on websites or other sources instead of within the actual advertisement. The FDA's plan to close this loophole will require more comprehensive disclosures and longer ads, potentially making them less appealing to companies. This development has sparked a reevaluation of the drug market, prompting investors to seek out the most promising stocks in this evolving landscape.

A recent analysis, using stock screeners and hedge fund sentiment data from Insider Monkey's database, identified the top 12 drug stocks with the highest number of hedge fund holders as of Q2 2025. Among these, Biogen Inc. (NASDAQ:BIIB) stands out with 55 hedge fund holders. Canaccord Genuity's Sumant Kulkarni recently reaffirmed a 'Buy' rating for Biogen, setting a price target of $220.00. The company's strong financial performance in Q2 2025, with a 7% year-over-year revenue growth and an increase in both GAAP and non-GAAP diluted EPS, further solidifies its position as a top pick.

As the FDA's actions reshape the pharmaceutical advertising landscape, investors are keenly watching these top drug stocks, anticipating the industry's response to this regulatory shift.

Go!